Cargando…

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms

Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of clonal disorders characterized by a high degree of clinical and molecular heterogeneity, and an invariable tendency to progress to acute myeloid leukemia. MDS typically present in the elderly with cyto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurnari, Carmelo, Xie, Zhuoer, Zeidan, Amer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063738/ https://www.ncbi.nlm.nih.gov/pubmed/36574201 http://dx.doi.org/10.1007/s44228-022-00024-4

Ejemplares similares

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
por: Awada, Hussein, et al.
Publicado: (2023)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
por: Lewis, Russell, et al.
Publicado: (2021)

Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
por: Pagliuca, Simona, et al.
Publicado: (2021)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Risk stratification in therapy-related myelodysplastic syndromes
por: Zeidan, Amer M.
Publicado: (2017)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes
por: Awada, Hussein, et al.
Publicado: (2022)

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
por: Clara, Joseph A., et al.
Publicado: (2016)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

The Role of Non-Coding RNAs in Myelodysplastic Neoplasms
por: Georgoulis, Vasileios, et al.
Publicado: (2023)

Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
por: Stahl, Maximilian, et al.
Publicado: (2020)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
por: Hochman, Michael J., et al.
Publicado: (2021)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Challenging the status flow: how artificial intelligence is advancing diagnosis of myelodysplastic neoplasms
por: Duetz, Carolien, et al.
Publicado: (2023)

From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression
por: Gurnari, Carmelo, et al.
Publicado: (2021)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
por: Shallis, Rory M., et al.
Publicado: (2018)

The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms
por: El Hussein, Siba, et al.
Publicado: (2022)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2023)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
por: Norasetthada, Lalita, et al.
Publicado: (2018)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

Impact of Next-Generation Sequencing in Diagnosis, Prognosis and Therapeutic Management of Acute Myeloid Leukemia/Myelodysplastic Neoplasms
por: Madaci, Lamia, et al.
Publicado: (2023)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

How I treat AML incorporating the updated classifications and guidelines
por: El Chaer, Firas, et al.
Publicado: (2023)

Ocular Tissue for Research in Australia: Strategies for Potential Research Utility of Surplus and Transplant-Ineligible Deceased Donations
por: Machin, Heather, et al.
Publicado: (2020)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms
por: WU, HUANLING, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_re6g4s708490an9g9pi5s1o7qr